MedTrace Logo

A Study of BCD-135 in Patients With Advanced Solid Tumors

NCT03464032 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-03-13

No results posted yet for this study

Summary

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors

Conditions

Interventions

DRUG

BCD-135

Monoclonal anti-PD-L1 antibody

Sponsors & Collaborators

  • Biocad

    lead INDUSTRY

Principal Investigators

  • Svetlana Odintsova, MD · LLC BioEk

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2018-05-31
Completion
2018-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03464032 on ClinicalTrials.gov